Envista price to sales ratio NVST
Market value divided by revenue over the last twelve months, since 2020.
- Today, Nov 2, 2026
- 1.4×
- 7-year median
- 1.6×
- Against its 7-year history
- 31st
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 0.7× to 3.2×
- Peer median
- 3.4×
Envista's price to sales ratio is 1.4× as of Nov 2, 2026.
That is below its 7-year median of 1.6×, lower than on 69% of days in the last 7 years.
Over that time it ranged from 0.7× in Mar 2020 to 3.2× in Mar 2022.
The median for 10 medical instruments and supplies stocks of a similar size is 3.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.4× | 1.3× | 1.8× |
| 2025 | 1.4× | 1.0× | 1.5× |
| 2024 | 1.3× | 1.1× | 1.6× |
| 2023 | 1.6× | 1.4× | 2.6× |
| 2022 | 2.1× | 2.1× | 3.2× |
| 2021 | 2.6× | 2.2× | 3.1× |
| 2020 | 2.4× | 0.7× | 2.4× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Envista's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| NVSTEnvista | 1.4× |
| ICUIICU Medical | 1.9× |
| BMIBadger Meter | 5.1× |
| VNTVontier | 1.6× |
| MMSIMerit Medical Systems | 3.1× |
| ATRCAtriCure | 5.3× |
| WRBYWarby Parker | 3.2× |
| HAEHaemonetics | 4.0× |
| UFPTUFP Technologies | 3.5× |
| MSAMSA Safety | 3.7× |
| INSPInspire Medical Systems | 2.2× |
| Peer median | 3.4× |
Where Envista ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Envista
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.